Dianthus Therapeutics (DNTH) Preferred Stock Liabilities (2017 - 2022)
Dianthus Therapeutics (DNTH) recorded quarterly Preferred Stock Liabilities of $118.0 million in Q4 2022, up 27.68% quarter-over-quarter from $92.4 million in Q4 2017.
Dianthus Therapeutics (DNTH) Preferred Stock Liabilities (2017 - 2022) Analysis & Trends
Dianthus Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $118.0 million for Q4 2022.
- In Q4 2022, Preferred Stock Liabilities changed N/A year-over-year to $118.0 million; the TTM figure through Dec 2022 stood at $118.0 million (changed N/A YoY), while the FY2022 annual figure was $118.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $118.0 million for Q4 2022 at Dianthus Therapeutics, up from $92.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $118.0 million in Q4 2022 to a low of $118.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 118.02 Mn |
| Dec 31, 2017 | 92.44 Mn |